Blood test developed in India to detect breast cancer gets US nod

Trial tests were conducted on over 20,000 women to see how quick the detection was

Breast cancer is increasing at an alarming rate and the awareness of the people regarding it will play a huge role in bringing down the number of its cases, said senior breast surgeon of Assam. 
In most cases, many painful tests were done to detect and diagnose various levels of breast cancer but now the US Food and Drug Administration granted a 'breakthrough designation' to a blood test developed in India by Datar Cancer Genetics that can detect early-stage breast cancer. 
The best part is that this test can now be done in India by Datar Cancer Genetics. The new test will provide an easier way to detect breast cancer with an accuracy of over 99 per cent, the company claimed.
The company has developed a new technology to detect the circulating tumour cells and cluster-specific to breast cancer with accuracy. In a statement, Datar Cancer Genetics said that the clinical trials have shown that the test can detect Stage 0 (DCIS) and Stage-1 breast cancer with an accuracy better than 99 per cent without any false positive.
The company conducted a clinical trial with over 20,000 women, comprising healthy and cancer patients. The test requires only five ml blood and does not involve exposure to any radiation or discomfort associated with mammography, Datara Genetics added in the statement.
"It is a matter of great pride that our scientists and clinicians from India have put the country at the centre stage of global cancer research and this is an example of the prime minister's Atmanirbhar Bharat mission," Rajan Datar said.
"This is for the first time that women above the age of 40 can obtain a breast cancer-specific blood test in consultation with their physician from the convenience and privacy of their home or office," Rajan Datar, Chairman, Datar Cancer Genetics said.
Logo of Datar Cancer Genetics
Image: Logo of Datar Cancer Genetics
He added that the approval from the US FDA "underscores the potential of the test which we believe will revolutionize the early detection and cure of this dreaded disease worldwide."
The test is already available in the European market and will be arriving in India shortly under the brand name 'EasyCheck'. While the company did not disclose the price range of the blood test, it said that they are in discussions with several leading healthcare providers for increased accessibility.
"It is a matter of great pride that our scientists and clinicians from India have put the country at the centre stage of global cancer research and this is an example of the prime minister's Atmanirbhar Bharat mission," Rajan Datar said.
Datar Cancer Genetics is a cancer research corporation that specializes in non-invasive techniques for diagnosing, treatment decisions, and management of cancer.



Be the first to start a discussion here. Sign-in to write a comment now!